|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.96 EUR | -2.36% |
|
-0.66% | -4.92% |
| Feb. 18 | Mirova Holds Less Than 5% of Voting Rights in MedinCell |  |
| Feb. 17 | Mirova Falls Below 5% Voting Rights Threshold in MedinCell | |
Company Valuation: MedinCell S.A.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 287.6 | 186.4 | 246.2 | 275.7 | 476.2 | 793.1 | - | - |
| Change | - | -35.19% | 32.11% | 11.97% | 72.7% | 66.57% | - | - |
| Enterprise Value (EV) 1 | 287.6 | 209.3 | 294.4 | 318.1 | 468.9 | 808.5 | 800.1 | 763.1 |
| Change | - | -27.23% | 40.69% | 8.03% | 47.42% | 72.44% | -1.04% | -4.62% |
| P/E ratio | -13.6x | -7.42x | -7.72x | -10.9x | -23.2x | -56.1x | 219x | 14.5x |
| PBR | - | -13.9x | -5.86x | -6.68x | -26.1x | 36.5x | 7.49x | 6.16x |
| PEG | - | -0.5x | -0.3x | 0.4x | 0.8x | 1.8x | -2x | 0x |
| Capitalization / Revenue | 35.1x | 45.6x | 24.9x | 30.5x | 18.7x | 25.1x | 18.5x | 8.62x |
| EV / Revenue | 35.1x | 51.2x | 29.8x | 35.2x | 18.4x | 25.6x | 18.7x | 8.3x |
| EV / EBITDA | - | -9.39x | -13.2x | -16.5x | -53x | -415x | 34.2x | 13.8x |
| EV / EBIT | -18.7x | -8.79x | -12.3x | -15.2x | -43.6x | -166x | 83.3x | 13.5x |
| EV / FCF | - | -9.1x | -13.4x | -24.3x | 26.3x | -42x | 95.8x | 20.7x |
| FCF Yield | - | -11% | -7.48% | -4.12% | 3.8% | -2.38% | 1.04% | 4.84% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.86 | -1 | -1.27 | -0.88 | -0.62 | -0.4273 | 0.1094 | 1.65 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 8.186 | 4.091 | 9.889 | 9.032 | 25.42 | 31.58 | 42.78 | 91.97 |
| EBITDA 1 | - | -22.3 | -22.36 | -19.26 | -8.85 | -1.95 | 23.37 | 55.49 |
| EBIT 1 | -15.37 | -23.81 | -24.02 | -20.94 | -10.76 | -4.884 | 9.606 | 56.72 |
| Net income 1 | -19.02 | -24.81 | -29.5 | -25.04 | -18.44 | -13.04 | 7.25 | 47.97 |
| Net Debt 1 | - | 22.87 | 48.18 | 42.34 | -7.296 | 15.35 | 6.95 | -30 |
| Reference price 2 | 11.70 | 7.42 | 9.81 | 9.59 | 14.40 | 23.96 | 23.96 | 23.96 |
| Nbr of stocks (in thousands) | 24,581 | 25,121 | 25,101 | 28,749 | 33,066 | 33,103 | - | - |
| Announcement Date | 6/16/21 | 6/14/22 | 6/26/23 | 6/10/24 | 6/17/25 | - | - | - |
1EUR in Million2EUR
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -57.44x | 26.21x | -424.53x | - | 961M | |
| 31.01x | 11.75x | 23.61x | 0.64% | 926B | |
| 24.77x | 6.01x | 16.36x | 2.18% | 586B | |
| 65.02x | 7.68x | 19.02x | 2.81% | 412B | |
| 19.35x | 4.81x | 11.94x | 2.72% | 382B | |
| 33.11x | 5.93x | 17.67x | 1.55% | 326B | |
| 21.99x | 6.1x | 15x | 2.65% | 317B | |
| 15.7x | 5.03x | 10.98x | 2.66% | 302B | |
| 14.77x | 5.12x | 10.74x | 3.51% | 218B | |
| 25.23x | 6.36x | 11.23x | 2.69% | 201B | |
| Average | 19.35x | 8.50x | -28.80x | 2.38% | 367.02B | |
| Weighted average by Cap. | 29.46x | 7.41x | 16.85x | 2.05% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- MEDCL Stock
- Valuation MedinCell S.A.
Select your edition
All financial news and data tailored to specific country editions
